Compared to current therapies, chimeric antigen receptor (CAR) T cell therapy can not just suppress the immune system, but partially reset it, interrupting the loop of chronic inflammation and tissue damage caused by autoimmune conditions like myositis. At the International Annual Patient Conference hosted by TMA on September 6-8, 2024, in Baltimore, Maryland, Dr. Maximillian…
Continue Reading
Dermatologist Dr. David Fiorentino is excited about the possibilities of cell therapies to treat autoimmune conditions like dermatomyositis (DM). In collaboration with rheumatologists and bone marrow transplant specialists at Stanford University, he is conducting a small, phase 1b clinical trial testing KYV-101, a CAR T cell therapy that targets a protein called CD19 on the…
Continue Reading
Recently, the FDA announced the approval of a new drug, vamorolone, as a treatment for Duchenne muscular dystrophy (DMD), a genetic muscle disease that usually affects young boys. Understandably, this news hasn’t made a big splash in myositis circles, but it should. Vamorolone, marketed under the name Agamree, is a corticosteroid drug with a twist….
Continue Reading